INTEGRATED FILING — Other than Banks



General information about company

Scrip code 000000
NSE Symbol MADHAVBAUG
MSEI Symbol NOTLISTED
ISIN INE0JR301013
Name of Company VAIDYA SANE AYURVED LABORATORIES LIMITED
Type of company SME
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 22-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 12-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Half Yearly
Reporting Quarter Yearly
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 22-May-2025   15:00:00
End date and time of board meeting 22-May-2025   17:55:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
(III) Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-05-22
Indicate Company website link for updated RPT policy of the Company https://madhavbaug.org/policies-and-code-of-conduct/
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 2
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable


Financial Results — Other than Bank
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Oct-2024 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Revenue From Operations
Revenue from operations 460953000 871103000
Other income 9497000 17691000
Total Income 470450000 888794000
2 Expenses
(a) Cost of materials consumed 0 0
(b) Purchases of stock-in-trade 119835000 237243000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0 0
(d) Employee benefit expense 92642000 186036000
(e) Finance costs 265000 1042000
(f) Depreciation and amortisation expense 19592000 37278000
(g) Other Expenses
1 Other Expenses 190675000 346488000
Total other expenses 190675000 346488000
Total expenses 423009000 808087000
3 Profit before exceptional and extraordinary items and tax 47441000 80707000
4 Exceptional items -12028000 -12028000
5 Profit before extraordinary items and tax 35413000 68679000
6 Extraordinary items 0 0
7 Profit before tax 35413000 68679000
8 Tax Expense
Current tax 8246000 18246000
Deferred tax 1816000 1467000
Total tax expenses 10062000 19713000
9 Net Profit Loss for the period from continuing operations 25351000 48966000
10 Profit (loss) from discontinuing operations before tax 0 0
11 Tax expense of discontinuing operations 0 0
12 Net profit (loss) from discontinuing operation after tax 0 0
13 Profit (loss) for period before minority interest 25351000 48966000
14 Share of profit (loss) of associates
15 Profit (loss) of minority interest
16 Net profit (Loss) for the period 25351000 48966000
17 Details of equity share capital
Paid-up equity share capital 105135000 105135000
Face value of equity share capital 10 10
18 Reserves excluding revaluation reserve 0
19 Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 2.41 4.66
Diluted earnings (loss) per share from continuing and discontinued operations 0.25 2.11
20 Debt equity ratio 0.0 2.0E-4
21 Debt service coverage ratio 0.0 1.027
22 Interest service coverage ratio 0.0 0.0
23 Disclosure of notes on financial results Textual Information(1)


Text Block
Textual Information(1) 1) The Audited Financial statement were reviewed by the audit committee and taken on record by the Board of directors at their meeting held on 22nd May, 2025. 2) As required under Regulation 33 of the SEBI (L0DR) Regulations, 2015, the Statutoiy Auditors have issued Audit Reports on the aforesaid audited financial results for the half year & year ended 31st March 2025, which were also approved by the Audit Committee and board at their meeting held on Thursday, 22nd May,2025. 3) The Earning Per Share (EPS) has been computed in accordance with the Accounting Standard on Earnings Per Share (AS 20).  4)  As per MCA Notification vide 16th February, 2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBl (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of IND-AS. As the company is covered under the exempted category. it has not adapted IND-AS for preparation of financial results. 5) The company has issued and allotted 27,71,200 equity share of face value INR 10/- each at a price of INR 73/- per share through an Initial Pubic Offer aggregating to INR 2022.98 lakhs. The net issue proceed after excluding Expenses is 1972.98 lakhs. The details of utilization of net IPO Proceeds is mentioned below, Particulars: - a) Branding & Advertising: - As per Prospectus 1,600.00 Actual Utilisation - 1,600.00 Pending Utilisation - 0.00 b) General Corporate Purpose: - As per Prospectus - 372.98 Actual Utilisation - 372.98 Pending Utilisation - 0.00 Note: The company had issued share warrant in April 2023, and it was subscribed by 2 subscribers and subsequently in August 23 10 subscribers applied for share warants, who paid application money of INR 13.43 Crores. In the November 2024 and February 2025 respectively, the warrant allotment date got expired and application money was forfeited vide special resolution dated 05th August 2023 dated 12 P.M. clause (a) and (g). The said receipt being of a capital nature credited to Capital reserve account.


Remarks
20 Debt equity ratio
21 Debt service coverage ratio Total debt service = Finance costs + Principal Repayments
22 Interest service coverage ratio


Cash flow statement — indirect
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
1 Statement of cash flows
Cash flows from used in operating activities
Profit before extraordinary items and tax 68679000
2 Adjustments for reconcile profit (loss)
Adjustments to profit (loss)
Adjustments for finance costs 1042000
Adjustments for depreciation and amortisation expense 37278000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for share-based payments 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 3324000
Other adjustments for non-cash items -88000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments to profit (loss) 41556000
3 Adjustments for working capital
Adjustments for decrease (increase) in inventories 10340000
Adjustments for decrease (increase) in trade receivables -15112000
Adjustments for decrease (increase) in other current assets 14072000
Adjustments for increase (decrease) in trade payables -14147000
Adjustments for increase (decrease) in other current liabilities -4688000
Adjustments for provisions -207000
Total adjustments for working capital -9742000
Total adjustments for reconcile profit (loss) 31814000
Net cash flows from (used in) operations 100493000
Dividends received -4000
Interest paid 0
Interest received -14477000
Income taxes paid (refund) 10185000
Other inflows (outflows) of cash -1000
Net cash flows from (used in) operating activities before extraordinary items 75826000
Proceeds from extraordinary items 0
Payment for extraordinary items 0
Net cash flows from (used in) operating activities 75826000
4 Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property plant and equipment 0
Purchase of property plant and equipment 72694000
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 2112000
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 4000
Interest received 14477000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -12954000
Proceeds from government grants 0
Net cash flows from (used in) investing activities before extraordinary items -69055000
Proceeds from extraordinary items 0
Payment for extraordinary items 0
Net cash flows from (used in) investing activities -69055000
Cash flows from used in financing activities
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 2181000
Dividends paid 0
Interest paid 1042000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -2194000
Net cash flows from (used in) financing activities before extraordinary items -5417000
Proceeds from extraordinary items 0
Payment for extraordinary items 0
Net cash flows from (used in) financing activities -5417000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 1354000
6 Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents -1000
Net increase (decrease) in cash and cash equivalents 1353000
Cash and cash equivalents cash flow statement at beginning of period 21852000
Cash and cash equivalents cash flow statement at end of period 23205000


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Equity and liabilities
1 Shareholders' funds
Share capital 105135000
Reserves and surplus 491872000
Money received against share warrants 0
Total shareholders' funds 597007000
2 Share application money pending allotment 0
3 Deferred government grants 0
4 Minority interest
5 Non-current liabilities
Long-term borrowings 0
Deferred tax liabilities (net) 1931000
Foreign currency monetary item translation difference liability account 0
Other long-term liabilities 12334000
Long-term provisions 15129000
Total non-current liabilities 29394000
6 Current liabilities
Short-term borrowings 14600000
Trade Payables
(A) Total outstanding dues of micro enterprises and small enterprises 6747000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 65778000
Total Trade payable 72525000
Other current liabilities 16069000
Short-term provisions 8693000
Total current liabilities 111887000
Total equity and liabilities 738288000
Assets
1 Non-current assets
i Property, Plant and Equipment and Intangible assets
Property, Plant and Equipment 192091000
Producing properties 0
Intangible assets 77562000
Preproducing properties 0
Property, Plant and Equipment capital work-in-progress 0
Intangible assets under development or work-in-progress 12618000
Total Property, Plant and Equipment and Intangible assets 282271000
ii Non-current investments 134499000
v Deferred tax assets (net) 0
vi Foreign currency monetary item translation difference asset account 0
vii Long-term loans and advances 65586000
viii Other non-current assets 0
Total non-current assets 482356000
Current assets
Current investments 129268000
Inventories 20230000
Trade receivables 70330000
Cash and cash equivalents 23205000
Bank balance other than cash and cash equivalents 0
Short-term loans and advances 12899000
Other current assets 0
Total current assets 255932000
Total assets 738288000
Disclosure of notes on assets and liabilities


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Oct-2024 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Hospital Activity 121071000 231987000
2 Sale of Product Activity 298930000 561162000
3 Common/unallocable 40954000 77954000
Total Segment Revenue 460955000 871103000
Less: Inter segment revenue
Revenue from operations 460955000 871103000
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Hospital Activity 70333000 131780000
2 Sale of Product Activity 184270000 334831000
3 Common/unallocable -199595000 -360654000
Total Profit before tax 55008000 105957000
i. Finance cost 0 0
ii. Other Unallocable Expenditure net off Unallocable income 29653000 56990000
Profit before tax 25355000 48967000
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Hospital Activity 175813000 175813000
2 Sale of Product Activity 0 0
3 Common/unallocable 571887000 571887000
Total Segment Asset 747700000 747700000
Un-allocable Assets 0 0
Net Segment Asset 747700000 747700000
4 Segment Liabilities
Segment Liabilities
1 Hospital Activity 3000000 3000000
2 Sale of Product Activity 0 0
3 Common/unallocable 744727000 744727000
Total Segment Liabilities 747727000 747727000
Un-allocable Liabilities 0 0
Net Segment Liabilities 747727000 747727000
Disclosure of notes on segments




Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 A A Mohare & Co Yes 31-Dec-2027


Financial details
Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income
2 Total Expenditure
3 Net Profit/(Loss)
4 Earnings Per Share
5 Total Assets
6 Total Liabilities
7 Net Worth


Signatories details

Name of CEO / Managing director
Name of CFO
Name of audit committee chairman
Name of statutory auditor
Name of other signatory, if any, with designation
Place
Date


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)
Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 27-May-2024
Amount Raised 2766875000000
Report filed for Quarter ended 31-Mar-2025
Monitoring Agency Not Applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review None- reviewed by the Audit Committee at its Meeting held on 22nd May, 2025
Comments of the auditors, if any None
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (2)
Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 14-Aug-2023
Amount Raised 10664460000000
Report filed for Quarter ended 31-Mar-2025
Monitoring Agency Not Applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review None- reviewed by the Audit Committee at its Meeting held on 22nd May, 2025
Comments of the auditors, if any None
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any


Signatory Details
Name of signatory Rohit Sane
Designation of person Managing Director
Place Thane
Date 22-May-2025


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 VAIDYA SANE AYURVED LABORATORIES LIMITED Dr. Rohit Madhav Sane Managing Director Remuneration 600000000000 Approved 600000000000 520000000 24230000000
2 VAIDYA SANE AYURVED LABORATORIES LIMITED Dr. Rohit Madhav Sane Managing Director Any other transaction Rent 578687400000 Approved 578687400000 0 0
3 VAIDYA SANE AYURVED LABORATORIES LIMITED Dr. Rohit Madhav Sane Managing Director Any other transaction Sale of Product 198102090000 Approved 198102090000 15055978000 10199953000
4 VAIDYA SANE AYURVED LABORATORIES LIMITED Dr. Vidyut Bipin Ghag Whole time Director Remuneration 199026000000 Approved 199026000000 0 0
5 VAIDYA SANE AYURVED LABORATORIES LIMITED Mr. Ratnakar Rai Independent Director Remuneration 21000000000 Approved 21000000000 10080000000 18900000000
6 VAIDYA SANE AYURVED LABORATORIES LIMITED Mr. Mahesh Kshirsagar Independent Director Remuneration 21000000000 Approved 21000000000 10080000000 18900000000
7 VAIDYA SANE AYURVED LABORATORIES LIMITED Mr. Sushrut Dambal Independent Director Remuneration 21000000000 Approved 21000000000 10080000000 18900000000
8 VAIDYA SANE AYURVED LABORATORIES LIMITED Mr. Narendra Pawar CFO (Appointed on 27-05-2024) Remuneration 124744000000 Approved 124744000000 0 0
9 VAIDYA SANE AYURVED LABORATORIES LIMITED Ms. Sapna Vaishnav CS ( Appointd on Date 17-08-2024) Remuneration 89012400000 Approved 89012400000 0 0
10 VAIDYA SANE AYURVED LABORATORIES LIMITED Mr. Shripad Upasani CEO (Exit Date 04-01-2025) Remuneration 457803300000 Approved 457803300000 0 0
11 VAIDYA SANE AYURVED LABORATORIES LIMITED Mr. Yogesh Walawalkar Senior VP Marketing Remuneration 281598000000 Approved 281598000000 0 0
12 VAIDYA SANE AYURVED LABORATORIES LIMITED Dr. Gurudatta Amin Chief Medical Officer Remuneration 248511800000 Approved 248511800000 0 0
13 VAIDYA SANE AYURVED LABORATORIES LIMITED Mr. Abhishek Deshpande CS ( Exit Date 01-06-2024) Remuneration 19616900000 Approved 19616900000 0 0
14 VAIDYA SANE AYURVED LABORATORIES LIMITED Mr. Darshan Shah CFO (Exit Date 26-05-2024) Remuneration 39690000000 Approved 39690000000 0 0
15 Aaharshastra Foodz Private Limited Mrs. Pooja Patil Directors Remuneration 42130000000 Approved 42130000000 0 0
16 Vaidya Sane Ayurved Laboratoies Limited Aaharshastra Foodz Private Limited Associate Company Any other transaction Profeesional Fees 42216342000 Approved 42216342000 614800000 654300000
17 Vaidya Sane Ayurved Laboratoies Limited Aaharshastra Foodz Private Limited Associate Company Inter-corporate deposit 11500000000 Approved 11500000000 48500000000 132664400000
18 Vaidya Sane Ayurved Laboratoies Limited F-Health Acceletors Private Limited Subsidiary Company Any other transaction Loans/Inter corporate Deposit 0 Approved 0 1000000000000 1000550000000
19 Vaidya Sane Ayurved Laboratoies Limited Joint Healing Services Private Limited Subsidiary Company Any other transaction Loans/Inter corporate Deposit 0 Approved 0 494487400000 494737400000
20 Dynamic Remedies Private Limited Kiran Bhide Director Remuneration 300000000000 Approved 300000000000 16976200000 33480000000
21 Dynamic Remedies Private Limited Kiran Bhide Director Any other transaction Expenses Reimbursment 739500000 Approved 739500000 1938800000 0
22 Dynamic Remedies Private Limited Rajeev Puranik Director (Exit Date 27-01-2025) Remuneration 11000000000 Approved 11000000000 0 0
23 Dynamic Remedies Private Limited Madura Bhide Director (Exit Date 23-10-2023) and Relative of Director of Holding Company Any other transaction Sale of Medicine 4346376000 Approved 4346376000 446700000 542700000
24 Dynamic Remedies Private Limited Dr Rekha Paralkar Relative of Director of Holding Company Any other transaction Sale of Medicine 12670283000 Approved 12670283000 0 305700000
25 Dynamic Remedies Private Limited Dr. Rohit Sane Managing Director of Holding Company Any other transaction Sale of Medicine 6622346000 Approved 6622346000 0 685100000
26 U V Ayrugen Private Limited Parikshit Bhide Director Remuneration 120000000000 Approved 120000000000 9483100000 8295900000
27 U V Ayrugen Private Limited Pradip Patil Director (Appointed ON 27/01/2025) Remuneration 19890000000 Approved 19890000000 0 9745000000
28 U V Ayrugen Private Limited Pradip Patil Director (Appointed ON 27/01/2025) Any other transaction Expenses Reimbursment 4500000000 Approved 4500000000 3000000000 0
29 U V Ayrugen Private Limited Dr. Rohit Sane Managing Director of Holding Company Any other transaction Expenses Reimbursment 3621000000 Approved 3621000000 315200000 0
30 U V Ayrugen Private Limited Sonali Patil Spouse of Director Any other transaction Professional Fees 4400000000 Approved 4400000000 360000000 0
31 U V Ayrugen Private Limited The feather knife Properitory concern of Relative of ceased Director Any other transaction Designing and Printing chgs 1300000000 Approved 1300000000 0 0
32 Vaidya Sane Ayurved Laboratoies Limited Vd Sane Ayurvedic Education and Agricuture Research Trust Entity Controlled by Pramotor Any other transaction sale of Services 15928298741000 Approved 15928298741000 1318899200000 1543925139000
33 Vaidya Sane Ayurved Laboratoies Limited Medemy Life Science Private Ltd Entity Controlled by Pramotor Any other transaction sale of goods 4419159013000 Approved 4419159013000 404880065000 772027357000
34 Vaidya Sane Ayurved Laboratoies Limited Medemy Life Science Private Ltd Entity Controlled by Pramotor Any other transaction Rent 141600000000 Approved 141600000000 0 10800000000
35 Vaidya Sane Ayurved Laboratoies Limited Easy Ayurveda Private Limtied Associate Company Interest received 293700000000 Approved 293700000000 166252191000 321351391000
36 Vaidya Sane Ayurved Laboratoies Limited Gurudatta Enterprises Relative of KMP is partner Any other transaction sale of goods 377535700000 Approved 377535700000 100955800000 83874100000
37 Vaidya Sane Ayurved Laboratoies Limited Cure and Care Private Limited Associate Company Any other transaction professional fees 94284000000 Approved 94284000000 87542100000 1755350000
Total value of transaction during the reporting period 24739305191000





Format for Disclosing Outstanding Default on Loans and Debt Securities
Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
3. Total financial indebtedness of the listed entity including short-term and long-term debt